Binnopharm Group increases production volumes of products for export from its Moscow region site
The Binnopharm Group production site, ALIUM plant in Moscow region, demonstrates a steady increase in production of medicines. The volume of output increased from 249 to 300 tons, which is an increase of 21% in the first half of 2025 compared to the second half of 2024. A significant increase was also recorded in the number of tablets produced − plus 10% compared to the previous period.
The production of drugs for export is actively underway. The volume of shipments to the CIS countries increased by 40% at once: from 3.7 to 5.1 million packages. Almost all key export markets of the near abroad showed growth, including Azerbaijan, Uzbekistan, Belarus, Georgia and Kyrgyzstan. The geography of supplies confirms stable interest in the company’s products outside of Russia and the high level of trust from international partners.
A significant contribution to the overall increase was provided by drugs from the most important therapeutic areas: cardiology, gynaecology, gastroenterology, and antibacterial therapy.
Anatoly Yaglenko, Corporate Director of Production: «The ALIUM production site, like other assets of Binnopharm Group, continues to increase the production of drugs. In accordance with the company’s development strategy, we are increasing production for export and successfully passing international audits at the same time. A new granulation line and a new packaging machine will be put into operation this year, which will enable the site to increase granulate production to 200 tonnes per annum and packaging by 15-20 million per annum».
Binnopharm Group continues to implement its sustainable growth strategy by increasing production capacity, strengthening export potential and maintaining a high standard of quality at every stage of production.
